Ototoxicité liée à la kanamycine au cours du traitement de la tuberculose multirésistante

Poka-Mayap, V.; Adamou, D. Balkissou; Pefura-Yone, E.W.; Kuaban, Christopher

doi:10.1016/j.rmr.2019.12.005

Cited by 7 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the veterinary and food-additive sectors, kanamycin (KAN) is a frequently used aminoglycoside antibiotic that restricts the growth and spread of microorganisms. 1 However, excessive use of KAN leaves biological remnants in the environment and food, which poses ototoxicity, 2 nephrotoxicity, 3 and other hazardous side-effects for the human body. Accordingly, establishment of a precise and reliable method for KAN detection to guarantee food safety and human health is crucial.…”

Section: Introductionmentioning

confidence: 99%

A novel colorimetric assay for sensitive detection of kanamycin based on the aptamer-regulated peroxidase-mimicking activity of Co₃O₄ nanoparticles

Zhou

et al. 2023

Anal. Methods

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

A novel colorimetric assay for sensitive detection of kanamycin based on the aptamer-regulated peroxidase-mimicking activity of Co₃O₄ nanoparticles

Zhou

et al. 2023

Anal. Methods

View full text Add to dashboard Cite

show abstract

Drugs in tuberculosis and leprosy

Onakpoya

2021

Side Effects of Drugs Annual

View full text Add to dashboard Cite

Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda

et al. 2023

View full text Add to dashboard Cite

Background Multi-drug-resistant tuberculosis (MDR-TB) treatment involves toxic drugs that cause adverse events (AEs), which are life-threatening and may lead to death if not well managed. In Uganda, the prevalence of MDR-TB is increasingly high, and about 95% of the patients are on treatment. However, little is known about the prevalence of AEs among patients on MDR-TB medicines. We therefore estimated the prevalence of reported adverse events (AEs) of MDR-TB drugs and factors associated with AEs in two health facilities in Uganda. Methods A retrospective cohort study of MDR-TB was conducted among patients enrolled at Mulago National Referral and Mbarara Regional Referral hospitals in Uganda. Medical records of MDR-TB patients enrolled between January 2015 and December 2020 were reviewed. Data on AEs, which were defined as irritative reactions to MDR-TB drugs, were extracted and analyzed. To describe reported AEs, descriptive statistics were computed. A modified Poisson regression analysis was used to determine factors associated with reported AEs. Results Overall, 369 (43.1%) of 856 patients had AEs, and 145 (17%) of 856 had more than one. Joint pain (244/369, or 66%), hearing loss (75/369, or 20%), and vomiting (58/369, or 16%) were the most frequently reported effects. Patients started on the 24-month regimen (adj. PR = 1.4, 95%; 1.07, 1.76) and individualized regimens (adj. PR = 1.5, 95%; 1.11, 1.93) were more likely to suffer from AEs. Lack of transport for clinical monitoring (adj. PR = 1.9, 95%; 1.21, 3.11); alcohol consumption (adj. PR = 1.2, 95%; 1.05, 1.43); and receipt of directly observed therapy from peripheral health facilities (adj. PR = 1.6, 95%; 1.10, 2.41) were significantly associated with experiencing AEs. However, patients who received food supplies (adj. PR = 0.61, 95%; 0.51, 0.71) were less likely to suffer from AEs. Conclusion The frequency of adverse events reported by MDR-TB patients is considerably high, with joint pain being the most common. Interventions such as the provision of food supplies, transportation, and consistent counseling on alcohol consumption to patients at initiation treatment facilities may contribute to a reduction in the rate of occurrence of AEs.

show abstract

Ototoxicité liée à la kanamycine au cours du traitement de la tuberculose multirésistante

Cited by 7 publications

References 14 publications

A novel colorimetric assay for sensitive detection of kanamycin based on the aptamer-regulated peroxidase-mimicking activity of Co₃O₄ nanoparticles

A novel colorimetric assay for sensitive detection of kanamycin based on the aptamer-regulated peroxidase-mimicking activity of Co₃O₄ nanoparticles

Drugs in tuberculosis and leprosy

Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda

Contact Info

Product

Resources

About

Ototoxicité liée à la kanamycine au cours du traitement de la tuberculose multirésistante

Cited by 7 publications

References 14 publications

A novel colorimetric assay for sensitive detection of kanamycin based on the aptamer-regulated peroxidase-mimicking activity of Co3O4 nanoparticles

A novel colorimetric assay for sensitive detection of kanamycin based on the aptamer-regulated peroxidase-mimicking activity of Co3O4 nanoparticles

Drugs in tuberculosis and leprosy

Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda

Contact Info

Product

Resources

About

A novel colorimetric assay for sensitive detection of kanamycin based on the aptamer-regulated peroxidase-mimicking activity of Co₃O₄ nanoparticles

A novel colorimetric assay for sensitive detection of kanamycin based on the aptamer-regulated peroxidase-mimicking activity of Co₃O₄ nanoparticles